EXACT Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti sold 7,667 shares of the stock in a transaction on Monday, November 12th. The shares were sold at an average price of $69.00, for a total value of $529,023.00. Following the transaction, the director now directly owns 102,786 shares in the company, valued at $7,092,234. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

EXAS stock traded down $3.22 during trading on Friday, reaching $71.70. The company’s stock had a trading volume of 1,385,229 shares, compared to its average volume of 1,349,683. EXACT Sciences Co. has a 1 year low of $37.36 and a 1 year high of $82.85. The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08. The firm has a market capitalization of $9.21 billion, a PE ratio of -72.42 and a beta of 1.20.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.05. The business had revenue of $118.29 million during the quarter, compared to analyst estimates of $109.33 million. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. EXACT Sciences’s revenue for the quarter was up 63.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.23) EPS. On average, sell-side analysts forecast that EXACT Sciences Co. will post -1.51 EPS for the current fiscal year.

Several equities research analysts have recently commented on the company. UBS Group set a $100.00 price objective on EXACT Sciences and gave the stock a “buy” rating in a research note on Thursday, November 29th. Cowen upped their price objective on EXACT Sciences from $65.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 5th. Goldman Sachs Group upped their price objective on EXACT Sciences to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, August 30th. BidaskClub lowered EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, October 11th. Finally, TheStreet upgraded EXACT Sciences from a “d” rating to a “c-” rating in a research note on Tuesday, November 6th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $84.08.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of EXACT Sciences by 2.6% during the third quarter. Vanguard Group Inc. now owns 10,498,087 shares of the medical research company’s stock valued at $828,509,000 after purchasing an additional 261,239 shares in the last quarter. William Blair Investment Management LLC grew its position in shares of EXACT Sciences by 28.7% during the third quarter. William Blair Investment Management LLC now owns 2,334,045 shares of the medical research company’s stock valued at $184,203,000 after purchasing an additional 520,579 shares in the last quarter. Zevenbergen Capital Investments LLC grew its position in shares of EXACT Sciences by 1.8% during the second quarter. Zevenbergen Capital Investments LLC now owns 2,070,170 shares of the medical research company’s stock valued at $123,775,000 after purchasing an additional 35,725 shares in the last quarter. Artisan Partners Limited Partnership grew its position in shares of EXACT Sciences by 25.8% during the second quarter. Artisan Partners Limited Partnership now owns 1,879,525 shares of the medical research company’s stock valued at $112,377,000 after purchasing an additional 385,766 shares in the last quarter. Finally, Frontier Capital Management Co. LLC grew its position in shares of EXACT Sciences by 37.7% during the third quarter. Frontier Capital Management Co. LLC now owns 1,585,851 shares of the medical research company’s stock valued at $125,155,000 after purchasing an additional 434,184 shares in the last quarter. Hedge funds and other institutional investors own 92.25% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: EXACT Sciences Co. (EXAS) Director Sells 7,667 Shares of Stock” was originally posted by Marea Informative and is the property of of Marea Informative. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.mareainformativa.com/news/2018/12/08/katherine-s-zanotti-sells-7667-shares-of-exact-sciences-co-exas-stock-updated-updated-updated.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: Retained Earnings

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.